Research programme: anti-EGFR therapeutics - Pharmexa

Drug Profile

Research programme: anti-EGFR therapeutics - Pharmexa

Alternative Names: EGFR AutoVac

Latest Information Update: 05 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmexa
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Sep 2007 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
  • 11 Jan 2005 Pharmexa and Epimmune have expanded their non-exclusive licence agreement of 2001 to include additional target antigens
  • 09 Jul 2004 Preclinical trials in Cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top